Topic: Pharmaceuticals

Latest content

Historic CRISPR drug approval heralds new era in Cas9 IP wars

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

17 November 2023

Regeneron asserts swathe of patents in latest Eylea biosimilar clash

Lawsuit is latest in a torrent of new BPCIA lawsuits to emerge over the past year

16 November 2023

Bristol-Myers fighting intense battle to keep Eliquis generics off European markets

What you need to know about one of 2023's most important patent wars

14 November 2023

FTC challenges 100 patent listings, tightening screws on pharma companies

The commission recently vowed to take action on alleged anticompetitive IP tactics

13 November 2023

German Stelara injunction is bad news for biosimilars using the EU SPC manufacturing waiver

Munich Regional Court has become the first to wade in on disputes over drugs exports under Europe’s SPC exemption

06 November 2023

CRISPR-Cas9 drugmakers like Vertex should come to the table early, says ToolGen’s IP chief

Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals

01 November 2023

Genentech and Biogen reach lightning-fast biosimilar truce as flurry of settlements continues

Latest agreement continues long-running pattern of dispute resolution tactics in biologics space

26 October 2023

UPC Court of Appeal hands down first decision at breakneck speed

Appellate court overturns Munich local division ruling in Amgen/Sanofi dispute

19 October 2023

Wave of biosimilars patent disputes hits the UK

Stelara IP wars continue to be waged in London, despite recent flurry of settlements

17 October 2023

RegenxBio/Sarepta dispute highlights strategic challenges for gene therapy developers

Narrow safe harbor immunity and platform technology patents are creating both pitfalls and opportunities

08 September 2023

Unlock unlimited access to all IAM content